Short Interest in Allarity Therapeutics, Inc. (NASDAQ:ALLR) Expands By 27.2%

Allarity Therapeutics, Inc. (NASDAQ:ALLR) was the recipient of a significant growth in short interest during the month of March. As of March 13th, there was short interest totaling 289,475 shares, a growth of 27.2% from the February 26th total of 227,623 shares. Currently, 1.8% of the company’s stock are sold short. Based on an average daily trading volume, of 256,750 shares, the days-to-cover ratio is currently 1.1 days.

Analyst Ratings Changes

A number of brokerages have weighed in on ALLR. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Allarity Therapeutics in a research report on Wednesday, January 21st. Ascendiant Capital Markets increased their price objective on Allarity Therapeutics from $9.25 to $9.50 and gave the company a “buy” rating in a report on Tuesday, December 9th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $9.50.

Allarity Therapeutics Price Performance

NASDAQ:ALLR opened at $1.07 on Monday. The company’s 50 day moving average is $1.05 and its 200-day moving average is $1.22. Allarity Therapeutics has a 12 month low of $0.61 and a 12 month high of $2.35. The firm has a market cap of $17.21 million, a price-to-earnings ratio of -1.81 and a beta of 0.20.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. XTX Topco Ltd bought a new stake in Allarity Therapeutics during the fourth quarter valued at about $36,000. Citadel Advisors LLC acquired a new stake in shares of Allarity Therapeutics in the third quarter valued at about $149,000. Private Advisor Group LLC bought a new position in shares of Allarity Therapeutics in the third quarter worth about $441,000. Renaissance Technologies LLC increased its stake in shares of Allarity Therapeutics by 274.1% in the fourth quarter. Renaissance Technologies LLC now owns 247,612 shares of the company’s stock worth $267,000 after purchasing an additional 181,426 shares during the period. Finally, DRW Securities LLC acquired a new position in shares of Allarity Therapeutics during the 4th quarter worth about $133,000. Institutional investors and hedge funds own 11.53% of the company’s stock.

Allarity Therapeutics Company Profile

Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.

The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials.